I am excited to keep moving forward
Third IndiCell PhD student to complete their mid-term review, fall 2024.
“Completing the mid-term review of my PhD on developing iPSC-based cell therapies for neurological disorders feels encouraging. It is an important milestone, highlighting progress in refining the production of neuroepithelial stem cells (NES) for regenerative medicine and tackling key production challenges such as GMP compliance and scalability.
My research focuses on two core questions:
1. How can the production of iPSC-derived NES cells be optimized to improve scalability and reduce costs?
2. What are the most effective strategies to ensure consistent quality and safety of iPSC-derived NES cells for therapeutic use?
As I reflect on the work, from developing microfluidic platforms to implementing robust quality control, I see the foundation we are laying to address these issues. I am motivated by the progress and excited to keep moving forward, knowing that these innovations can bring us closer to clinical applications.” says Alice, who is doing her PhD in Anna Falk’s lab at Lund University after the mid-term review.
